Phase II trial of Didemnin B in patients with advanced renal cell carcinoma Academic Article Article uri icon

Overview

MeSH Major

  • Antigens, Neoplasm
  • Gene Expression Regulation, Developmental
  • Membrane Proteins
  • Neoplasm Proteins
  • Placenta
  • Trophoblasts

abstract

  • Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.

publication date

  • November 1990

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1007/BF00198598

PubMed ID

  • 2084073

Additional Document Info

start page

  • 391

end page

  • 2

volume

  • 8

number

  • 4